Moderna's existing manufacturing footprint, include key U.S. facilities and facilities under construction in Australia and the U.K. The facility will proceed with final qualification process, ...

STONY BROOK, NY and JUPITER, FL / ACCESSWIRE / March 18, 2024 /Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the Company), a leader in PCR-based DNA technologies, and Alphazyme LLC ...

BURLINGTON, Mass., Sept. 26, 2023 /PRNewswire/ -- MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, is the first CTDMO (contract testing, development and ...

The COVID-19 pandemic brought messenger RNA (mRNA) vaccines to the forefront of global health care. After their clinical ...

RIO RANCHO, N.M.--(BUSINESS WIRE)--Nature’s Toolbox (NTx), a life sciences company developing next-generation platforms for RNA and protein manufacturing, today launched NTx Services. This new service ...

From global vaccines to personalized cancer therapies, mRNA is being considered across several clinical applications, which ultimately creates varying requirements in terms of production scale and ...

NAIROBI, Dec 18 (Reuters) - COVID-19 vaccine maker BioNTech (22UAy.DE), opens new tab aims to start production at its mRNA vaccine factory site in Rwanda in 2025, company officials said on Monday, the ...

The success of the mRNA-based vaccines against SARS-CoV-2 merely hint at the healthcare implications of mRNA technology. More mRNA-based vaccines are in the works, as are mRNA-based therapeutics for ...

CAMBRIDGE, MA / ACCESS Newswire / November 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced the expansion of its U.S. manufacturing capabilities with the onshoring of Drug Product manufacturing ...

Stay ahead in the booming mRNA market, projected to reach $63.28 billion by 2025, with the 3 rd mRNA Process Development & Manufacturing Summit 2025 - Europe’s premier industry-focused forum dedicated ...

HEIDELBERG, Germany--(BUSINESS WIRE)--AGC Biologics today announced it is partnering with Repair Biotechnologies to tackle one of the world's most persistent health challenges and cause of mortality.

New capabilities strengthen U.S. production, completing Moderna’s domestic end-to-end mRNA manufacturing network More than $140 million investment will create hundreds of highly skilled ...